Prithvi Mruthyunjaya, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 23
- 5 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · County of Santa Clara
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
23 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mruthyunjaya’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
23 of 23 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C144368 · Current
Licensed to practise in California · since 2016 · expires 2028-03-31 · Albany Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$117,067
Medicare paid this office $117,067 for 466 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 312 | $30,275 | $66 |
| Injection of drug into eye | 56 | $20,784 | $85 |
| Imaging of retina | 386 | $16,156 | $22 |
| Established patient problem focused exam of visual system | 75 | $4,434 | $43 |
| 2d ultrasound scan of eye tissue and structures | 119 | $3,955 | $26 |
See all 17 services
| Established patient complete exam of visual system | 312 | $30,275 | $66 |
| Injection of drug into eye | 56 | $20,784 | $85 |
| Imaging of retina | 386 | $16,156 | $22 |
| Established patient problem focused exam of visual system | 75 | $4,434 | $43 |
| 2d ultrasound scan of eye tissue and structures | 119 | $3,955 | $26 |
| New patient complete exam of visual system | 39 | $2,826 | $72 |
| Return visit (30+ min) | 31 | $2,783 | $87 |
| New patient visit (45+ min) | 25 | $2,736 | $109 |
| New patient visit (60+ min) | 17 | $2,601 | $153 |
| Short return visit (20+ min) | 26 | $2,033 | $56 |
| Ultrasound scan of eye using water bath method | 46 | $1,499 | $27 |
| Extended exam of the back part of the eye with retinal drawing | 30 | $605 | $20 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 12 | $552 | $39 |
| Photography of the retina | 20 | $393 | $19 |
| Exam of visual field with extended testing | 12 | $349 | $25 |
| Photography of content of eyes | 86 | $325 | $3 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 17 | $254 | $15 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
466 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 14% · Women 56% · Also on Medicaid 16% · Health risk score 1.55. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 64% · Diabetes 24% · Coronary heart disease 24% · Cancer 22% · Chronic kidney disease 21% · Atrial fibrillation 15% · Depression 13% · Heart failure 12% · COPD 8% · Stroke 7% · Dementia 5%.
The office billed $1,109,579, Medicare allowed $155,923 and paid $117,067; for 2,230 services of 49 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 466 | 2,230 | 75 | 1.55 | $1,109,579 | $117,067 |
| 2023 | 522 | 2,279 | 75 | 1.70 | $1,003,171 | $128,448 |
| 2022 | 570 | 2,328 | 75 | 1.57 | $956,340 | $131,316 |
| 2021 | 551 | 2,200 | 74 | 1.62 | $811,495 | $124,351 |
| 2020 | 418 | 1,821 | 73 | 1.69 | $762,079 | $115,733 |
| 2019 | 399 | 1,730 | 73 | 1.56 | $598,914 | $100,676 |
| 2018 | 297 | 1,216 | 73 | 1.43 | $332,171 | $63,850 |
| 2017 | 178 | 569 | 73 | 1.50 | $283,594 | $48,643 |
| 2016 | 482 | 1,854 | 74 | 1.15 | $872,029 | $241,069 |
| 2015 | 685 | 3,963 | 74 | 1.11 | $1,849,657 | $574,473 |
| 2014 | 682 | 4,436 | 74 | 1.14 | $1,862,528 | $598,113 |
| 2013 | 709 | 5,011 | 74 | 1.20 | $2,137,600 | $705,287 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Established patient complete exam of visual system | 329 | $32,490 | $68 |
| Injection of drug into eye | 58 | $20,485 | $89 |
| Imaging of retina | 437 | $17,417 | $23 |
| New patient complete exam of visual system | 72 | $6,129 | $85 |
| Established patient problem focused exam of visual system | 64 | $4,174 | $47 |
| 2d ultrasound scan of eye tissue and structures | 105 | $4,130 | $28 |
| New patient visit (45+ min) | 24 | $2,759 | $115 |
| Return visit (30+ min) | 27 | $2,560 | $88 |
| Extended exam of the back part of the eye with retinal drawing | 75 | $1,565 | $20 |
| Short return visit (20+ min) | 24 | $1,477 | $57 |
| Ultrasound scan of eye using water bath method | 45 | $1,396 | $28 |
| Photography of the retina | 25 | $523 | $18 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 11 | $519 | $40 |
| Imaging of retina | 17 | $420 | $20 |
| Photography of content of eyes | 77 | $261 | $3 |
2022: 16 services
| Established patient complete exam of visual system | 330 | $30,998 | $63 |
| Injection of drug into eye | 54 | $19,908 | $82 |
| Imaging of retina | 475 | $18,356 | $22 |
| New patient complete exam of visual system | 89 | $7,504 | $84 |
| New patient visit (45+ min) | 38 | $4,395 | $116 |
| Established patient problem focused exam of visual system | 68 | $3,689 | $44 |
| 2d ultrasound scan of eye tissue and structures | 81 | $2,641 | $26 |
| New patient visit (60+ min) | 16 | $2,516 | $157 |
| Return visit (30+ min) | 27 | $2,405 | $89 |
| Ultrasound scan of eye using water bath method | 40 | $1,313 | $30 |
| Short return visit (20+ min) | 19 | $1,180 | $59 |
| Imaging of retina | 34 | $917 | $18 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 17 | $718 | $38 |
| Photography of the retina | 29 | $608 | $20 |
| Exam of visual field with extended testing | 15 | $328 | $22 |
| Photography of content of eyes | 64 | $214 | $3 |
2021: 20 services
| Established patient complete exam of visual system | 294 | $28,244 | $66 |
| Imaging of retina | 445 | $17,728 | $23 |
| Injection of drug into eye | 53 | $14,772 | $82 |
| New patient visit (45+ min) | 55 | $6,628 | $121 |
| New patient complete exam of visual system | 72 | $6,111 | $85 |
| Established patient problem focused exam of visual system | 61 | $3,738 | $47 |
| Injection of drug into eye | 12 | $2,601 | $84 |
| Return visit (30+ min) | 31 | $2,568 | $73 |
| 2d ultrasound scan of eye tissue and structures | 59 | $1,974 | $27 |
| New patient visit (60+ min) | 11 | $1,709 | $155 |
| Imaging of retina | 47 | $1,512 | $20 |
| Short return visit (20+ min) | 27 | $1,479 | $51 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 31 | $1,347 | $41 |
| New patient visit (30+ min) | 17 | $1,121 | $66 |
| Short return visit (20+ min) | 14 | $808 | $58 |
| Ultrasound scan of eye using water bath method | 22 | $740 | $27 |
| 1d and 2d ultrasound scan of eye tissue and structures | 18 | $648 | $36 |
| Short return visit | 27 | $616 | $22 |
| Photography of the retina | 14 | $341 | $20 |
| Photography of content of eyes | 72 | $249 | $2 |
2020: 20 services
| Established patient complete exam of visual system | 183 | $18,007 | $66 |
| Imaging of retina | 314 | $12,995 | $22 |
| Injection of drug into eye | 31 | $11,881 | $86 |
| New patient visit (45+ min) | 71 | $8,227 | $116 |
| Injection of drug into eye | 18 | $3,648 | $99 |
| Established patient problem focused exam of visual system | 48 | $3,170 | $45 |
| New patient visit (60+ min) | 18 | $2,682 | $149 |
| Long return visit (40+ min) | 24 | $1,877 | $78 |
| Imaging of retina | 61 | $1,769 | $20 |
| Short return visit (20+ min) | 33 | $1,616 | $45 |
| Short return visit (20+ min) | 30 | $1,401 | $38 |
| 1d and 2d ultrasound scan of eye tissue and structures | 30 | $1,357 | $42 |
| New patient complete exam of visual system | 14 | $1,266 | $90 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 23 | $1,251 | $42 |
| 2d ultrasound scan of eye tissue and structures | 40 | $1,243 | $26 |
| Return visit (30+ min) | 13 | $875 | $67 |
| Short return visit | 27 | $775 | $20 |
| Extended exam of the back part of the eye with retinal drawing | 18 | $325 | $18 |
| Photography of the retina | 15 | $308 | $19 |
| Photography of content of eyes | 47 | $240 | $2 |
2019: 21 services
| Established patient complete exam of visual system | 163 | $15,207 | $67 |
| Imaging of retina | 303 | $13,229 | $23 |
| Injection of drug into eye | 27 | $11,004 | $89 |
| New patient visit (45+ min) | 59 | $6,647 | $113 |
| Established patient problem focused exam of visual system | 70 | $4,736 | $45 |
| New patient complete exam of visual system | 52 | $4,263 | $82 |
| Long return visit (40+ min) | 25 | $2,524 | $101 |
| Injection of drug into eye | 14 | $2,348 | $98 |
| 1d and 2d ultrasound scan of eye tissue and structures | 30 | $1,972 | $53 |
| Imaging of retina | 38 | $1,206 | $24 |
| Return visit (30+ min) | 12 | $1,077 | $72 |
| Established patient problem focused exam of visual system | 19 | $1,044 | $50 |
| Short return visit (20+ min) | 19 | $794 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 17 | $792 | $36 |
| 2d ultrasound scan of eye tissue and structures | 18 | $774 | $29 |
| Short return visit (20+ min) | 18 | $696 | $35 |
| Short return visit | 21 | $672 | $22 |
| Ultrasound scan of eye using water bath method | 14 | $410 | $26 |
| Photography of content of eyes | 59 | $348 | $3 |
| Examination of eye by ophthalmoscope with retinal drawing | 11 | $272 | $15 |
| Photography of the retina | 14 | $264 | $19 |
2018: 16 services
| Injection of drug into eye | 16 | $8,982 | $93 |
| Imaging of retina | 213 | $8,786 | $23 |
| Established patient complete exam of visual system | 70 | $5,023 | $70 |
| New patient visit (45+ min) | 48 | $4,904 | $102 |
| Short return visit (20+ min) | 78 | $4,537 | $42 |
| Return visit (30+ min) | 52 | $4,064 | $66 |
| New patient complete exam of visual system | 53 | $3,995 | $75 |
| 1d and 2d ultrasound scan of eye tissue and structures | 29 | $2,182 | $68 |
| New patient visit (60+ min) | 11 | $1,656 | $151 |
| Short return visit | 38 | $1,525 | $22 |
| New patient visit (30+ min) | 21 | $1,359 | $65 |
| 2d ultrasound scan of eye tissue and structures | 25 | $1,304 | $41 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 27 | $1,200 | $36 |
| Established patient problem focused exam of visual system | 14 | $738 | $49 |
| Examination of eye by ophthalmoscope with retinal drawing | 22 | $463 | $17 |
| Photography of content of eyes | 30 | $167 | $3 |
2017: 15 services
| New patient visit (45+ min) | 45 | $5,082 | $113 |
| 1d and 2d ultrasound scan of eye tissue and structures | 27 | $2,619 | $75 |
| Return visit (30+ min) | 31 | $2,375 | $64 |
| Imaging of retina | 71 | $2,316 | $23 |
| New patient complete exam of visual system | 24 | $2,069 | $86 |
| Established patient complete exam of visual system | 24 | $1,927 | $74 |
| Short return visit (20+ min) | 36 | $1,917 | $43 |
| New patient visit (60+ min) | 11 | $1,654 | $150 |
| Long return visit (40+ min) | 15 | $1,295 | $86 |
| Established patient problem focused exam of visual system | 16 | $933 | $49 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 17 | $777 | $39 |
| New patient visit (30+ min) | 11 | $714 | $65 |
| Examination of eye by ophthalmoscope with retinal drawing | 29 | $643 | $18 |
| Short return visit | 18 | $568 | $23 |
| Photography of content of eyes | 16 | $75 | $3 |
2016: 15 services
| Injection, aflibercept, 1 mg | 28 | $97,314 | None |
| Established patient complete exam of visual system | 270 | $20,873 | $73 |
| 1d and 2d ultrasound scan of eye tissue and structures | 112 | $14,237 | $110 |
| Established patient problem focused exam of visual system | 144 | $7,843 | $50 |
| Injection of drug into eye | 48 | $6,734 | $67 |
| Imaging of retina | 218 | $5,031 | $19 |
| Imaging of retina | 144 | $4,664 | $27 |
| New patient complete exam of visual system | 44 | $4,569 | $104 |
| 2d ultrasound scan of eye tissue and structures | 54 | $4,252 | $62 |
| Injection of drug into eye | 21 | $2,962 | $71 |
| Ultrasound scan of eye using water bath method | 40 | $2,648 | $58 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 56 | $2,449 | $33 |
| Injection of drug or substance into membrane covering eyeball | 13 | $718 | $42 |
| Exam of the internal drainage system of eye | 14 | $284 | $20 |
| Photography of content of eyes | 24 | $49 | $2 |
2015: 25 services
| Injection, aflibercept, 1 mg | 34 | $267,821 | None |
| Injection, ranibizumab, 0.1 mg | 12 | $70,707 | None |
| Established patient complete exam of visual system | 451 | $51,397 | $82 |
| Injection of drug into eye | 65 | $20,116 | $73 |
| 2d ultrasound scan of eye tissue and structures | 206 | $19,246 | $68 |
| Established patient problem focused exam of visual system | 202 | $15,969 | $57 |
| Imaging of retina | 253 | $15,590 | $32 |
| Destruction of growth of retina by implantation of radiation source | 13 | $13,735 | $1,057 |
| New patient complete exam of visual system | 106 | $11,621 | $110 |
| Imaging of retina | 298 | $9,153 | $20 |
| Injection of drug into eye | 43 | $7,937 | $75 |
| Removal of eyeball with insertion of implant attached to muscles | 11 | $7,068 | $643 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 90 | $5,373 | $35 |
| 1d and 2d ultrasound scan of eye tissue and structures | 32 | $4,108 | $121 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 33 | $3,757 | $77 |
| Ultrasound scan of eye using water bath method | 37 | $3,426 | $65 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 12 | $3,128 | $174 |
| Unclassified biologics | 14 | $1,658 | None |
| Injection of drug or substance into membrane covering eyeball | 22 | $1,232 | $46 |
| Examination of eye by ophthalmoscope with retinal drawing | 32 | $792 | $18 |
| Examination of eye by ophthalmoscope with retinal drawing | 17 | $554 | $21 |
| Exam of the internal drainage system of eye | 26 | $527 | $19 |
| Short return visit (20+ min) | 18 | $420 | $23 |
| Photography of the retina | 20 | $354 | $15 |
| Photography of content of eyes | 45 | $101 | $2 |
2014: 20 services
| Injection, aflibercept, 1 mg | 29 | $284,197 | None |
| Injection, ranibizumab, 0.1 mg | 15 | $71,794 | None |
| Established patient complete exam of visual system | 357 | $37,795 | $83 |
| Established patient problem focused exam of visual system | 287 | $28,447 | $61 |
| Injection of drug into eye | 70 | $22,953 | $73 |
| Imaging of retina | 286 | $17,831 | $32 |
| 2d ultrasound scan of eye tissue and structures | 176 | $17,399 | $68 |
| New patient complete exam of visual system | 123 | $13,049 | $106 |
| Imaging of retina | 304 | $9,750 | $20 |
| Injection of drug into eye | 45 | $9,110 | $68 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 104 | $6,187 | $32 |
| Ultrasound scan of eye using water bath method | 42 | $3,983 | $66 |
| Examination of eye by ophthalmoscope with retinal drawing | 112 | $3,398 | $20 |
| Examination of eye by ophthalmoscope with retinal drawing | 116 | $2,974 | $18 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 23 | $2,899 | $74 |
| Unclassified biologics | 22 | $1,753 | None |
| Injection of drug or substance into membrane covering eyeball | 21 | $1,566 | $56 |
| Exam of the internal drainage system of eye | 36 | $816 | $21 |
| Short return visit (20+ min) | 11 | $602 | $55 |
| Photography of content of eyes | 58 | $155 | $2 |
2013: 20 services
| Injection, aflibercept, 1 mg | 31 | $257,922 | None |
| Injection, ranibizumab, 0.1 mg | 27 | $177,672 | None |
| Established patient problem focused exam of visual system | 427 | $39,966 | $56 |
| Injection of drug into eye | 84 | $27,827 | $70 |
| Established patient complete exam of visual system | 264 | $24,086 | $84 |
| Imaging of retina | 309 | $21,955 | $31 |
| 2d ultrasound scan of eye tissue and structures | 142 | $12,331 | $67 |
| Injection of drug into eye | 50 | $11,244 | $68 |
| New patient complete exam of visual system | 104 | $10,654 | $102 |
| Imaging of retina | 261 | $8,624 | $20 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 34 | $5,160 | $78 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 78 | $4,711 | $33 |
| Examination of eye by ophthalmoscope with retinal drawing | 148 | $3,804 | $17 |
| Ultrasound scan of eye using water bath method | 38 | $3,056 | $69 |
| Examination of eye by ophthalmoscope with retinal drawing | 82 | $2,721 | $19 |
| Unclassified biologics | 30 | $2,545 | None |
| Injection of drug or substance into membrane covering eyeball | 21 | $1,647 | $59 |
| Exam of the internal drainage system of eye | 27 | $577 | $19 |
| Photography of the retina | 11 | $193 | $18 |
| Photography of content of eyes | 37 | $79 | $2 |
Medicaid work
$4,255 in 2024
Medicaid paid $4,255 for 229 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 151 | $2,391 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 78 | $1,864 |
| 2024 | 229 | 2 | 27 | $4,255 |
| 2023 | 454 | 3 | 34 | $6,773 |
| 2022 | 509 | 3 | 30 | $7,967 |
| 2021 | 506 | 3 | 29 | $5,514 |
| 2020 | 501 | 4 | 36 | $6,171 |
| 2019 | 374 | 3 | 28 | $4,635 |
| 2018 | 206 | 2 | 20 | $1,330 |
See the largest Medicaid services in earlier years
2023
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 288 | $3,993 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 153 | $2,742 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 13 | $38 |
2022
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 361 | $4,265 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 135 | $3,036 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 13 | $666 |
2021
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 409 | $4,048 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 70 | $1,444 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 27 | $22 |
2020
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 445 | $3,899 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 27 | $1,732 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 16 | $385 |
| Short return visit (20+ min) | 13 | $156 |
2019
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 323 | $3,610 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 33 | $833 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 18 | $192 |
2018
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 119 | $784 |
| Short return visit (20+ min) | 87 | $546 |
Drugs they prescribed that Part D paid
$3,776
Pharmacies billed $3,776 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 152) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
96 generic and 56 brand-name prescriptions · $3,776 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 47 | $1,929 | $41 |
| Ketorolac Tromethamine | 33 | $361 | $11 |
| Brimonidine | 12 | $329 | $27 |
Year by year
| 2024 | 152 | 50 | 0% (0) | 37% | $3,776 |
| 2023 | 143 | 58 | 0% (0) | 46% | $10,388 |
| 2022 | 287 | 72 | 0% (0) | 38% | $17,481 |
| 2021 | 205 | 70 | 0% (0) | 44% | $16,368 |
| 2020 | 143 | 57 | None | 43% | $10,466 |
| 2019 | 117 | 40 | 0% (0) | 53% | $14,840 |
| 2018 | 155 | 46 | 0% (0) | 46% | $14,214 |
| 2017 | 110 | 40 | 0% (0) | 65% | $12,411 |
| 2016 | 233 | 68 | 0% (0) | 56% | $21,083 |
| 2015 | 326 | 102 | None | 68% | $29,538 |
| 2014 | 341 | 92 | None | 64% | $35,634 |
| 2013 | 283 | 86 | None | 63% | $35,790 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Prednisolone Acetate | 36 | $1,924 | $53 |
| Ketorolac Tromethamine | 20 | $725 | $36 |
| Brimonidine | 19 | $430 | $23 |
2022: 8 drugs
| Prednisolone Acetate | 54 | $3,737 | $69 |
| Ketorolac Tromethamine | 56 | $3,016 | $54 |
| Moxifloxacin | 21 | $610 | $29 |
| Brimonidine | 35 | $393 | $11 |
| Latanoprost | 25 | $317 | $13 |
| Atropine Sulfate | 11 | $274 | $25 |
| Neomycin-Polymyxin-Dexameth | 16 | $217 | $14 |
| Timolol Maleate | 11 | $80 | $7 |
2021: 5 drugs
| Prednisolone Acetate | 48 | $3,509 | $73 |
| Ketorolac Tromethamine | 38 | $1,505 | $40 |
| Latanoprost | 19 | $417 | $22 |
| Brimonidine | 14 | $416 | $30 |
| Moxifloxacin | 19 | $392 | $21 |
2020: 3 drugs
| Prednisolone Acetate | 33 | $2,009 | $61 |
| Ketorolac Tromethamine | 19 | $727 | $38 |
| Erythromycin | 12 | $134 | $11 |
2019: 2 drugs
| Prednisolone Acetate | 28 | $1,559 | $56 |
| Ketorolac Tromethamine | 17 | $548 | $32 |
2018: 2 drugs
| Prednisolone Acetate | 31 | $1,581 | $51 |
| Ketorolac Tromethamine | 19 | $921 | $48 |
2017: 2 drugs
| Prednisolone Acetate | 28 | $2,070 | $74 |
| Ketorolac Tromethamine | 11 | $728 | $66 |
2016: 5 drugs
| Brimonidine | 28 | $3,412 | $122 |
| Prednisolone Acetate | 42 | $1,706 | $41 |
| Valacyclovir | 13 | $1,423 | $109 |
| Ketorolac Tromethamine | 34 | $1,118 | $33 |
| Dorzolamide-Timolol | 22 | $386 | $18 |
2015: 9 drugs
| Prolensa | 16 | $3,820 | $239 |
| Nevanac | 15 | $3,373 | $225 |
| Prednisolone Acetate | 64 | $3,328 | $52 |
| Brimonidine | 41 | $3,029 | $74 |
| Combigan | 14 | $1,700 | $121 |
| Timolol Maleate | 24 | $1,533 | $64 |
| Ketorolac Tromethamine | 27 | $944 | $35 |
| Dorzolamide-Timolol | 16 | $325 | $20 |
| Latanoprost | 13 | $309 | $24 |
2014: 8 drugs
| Prolensa | 47 | $9,098 | $194 |
| Nevanac | 19 | $4,158 | $219 |
| Prednisolone Acetate | 63 | $3,800 | $60 |
| Bromfenac | 25 | $3,312 | $132 |
| Brimonidine | 32 | $2,095 | $65 |
| Combigan | 18 | $1,999 | $111 |
| Dorzolamide-Timolol | 15 | $380 | $25 |
| Dorzolamide | 13 | $345 | $27 |
2013: 8 drugs
| Nevanac | 38 | $6,266 | $165 |
| Bromday | 19 | $4,078 | $215 |
| Travatan Z | 11 | $1,397 | $127 |
| Prednisolone Acetate | 41 | $1,307 | $32 |
| Dorzolamide-Timolol | 20 | $924 | $46 |
| Brimonidine | 16 | $792 | $50 |
| Gentamicin Sulfate | 11 | $134 | $12 |
| Timolol Maleate | 15 | $111 | $7 |
Money from drug and device companies
$584 in 2025
| 2025 | 3 | 8 | None | $584 |
| 2024 | 4 | 10 | $17,500 | $19,177 |
| 2023 | 7 | 17 | $21,135 | $23,334 |
| 2022 | 7 | 16 | $13,135 | $17,080 |
| 2021 | 2 | 6 | $7,955 | $8,151 |
| 2020 | 2 | 2 | $5,505 | $5,505 |
| 2019 | 4 | 5 | None | $406 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Unity | $494 | 5 payments
|
| Apellis Pharmaceuticals | Syfovre | $58 | 2 payments
|
| Genentech USA | Susvimo | $32 | 1 payment
|
See all 8 published payments
| Apellis Pharmaceuticals | Meals · 2025-10-11 | Syfovre | $30 |
| Apellis Pharmaceuticals | Meals · 2025-10-11 | Syfovre | $28 |
| Alcon Vision | Meals · 2025-09-12 | Unity | $140 |
| Genentech USA | Meals · 2025-08-14 | Susvimo | $32 |
| Alcon Vision | Meals · 2025-06-21 | Unity | $170 |
| Alcon Vision | Meals · 2025-01-09 | Constellation | $20 |
| Alcon Vision | Travel · 2025-01-09 | Constellation | $76 |
| Alcon Vision | Travel · 2025-01-09 | Constellation | $87 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $19,177
| Alcon Vision | Constellation | $18,760 | 5 payments
|
| Regeneron Pharmaceuticals | Eylea | $180 | 2 payments
|
| Immunocore | Kimmtrak | $125 | 2 payments
|
| Bausch & Lomb Americas | Stellaris | $112 | 1 payment
|
2023: $23,334
| Alcon Vision | Constellation | $14,003 | 7 payments
|
| Amgen | None | $4,915 | 2 payments
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $2,328 | 3 payments
|
| ImmunoGen | None | $1,127 | 2 payments
|
| Alcon Research | None | $700 | 1 payment
|
| Astellas Pharma US | None | $149 | 1 payment
|
| EyePoint Pharmaceuticals US | Eyp-1901 | $111 | 1 payment
|
2022: $17,080
| Alcon Vision | Luxor | $12,421 | 8 payments
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $3,149 | 2 payments
|
| Bausch & Lomb Americas | Xipere | $1,035 | 1 payment
|
| Genentech | Vabysmo | $214 | 2 payments
|
| Carl Zeiss Meditec USA | Artevo 800 | $123 | 1 payment
|
| Alimera Sciences | Iluvien | $107 | 1 payment
|
| Genentech USA | Susvimo | $31 | 1 payment
|
2021: $8,151
| Alcon Vision | Constellation | $5,685 | 4 payments
|
| Genentech USA | Lucentis | $2,466 | 2 payments
|
2020: $5,505
| Alcon Vision | Constellation | $3,150 | 1 payment
|
| Genentech USA | Lucentis | $2,355 | 1 payment
|
2019: $406
| Alimera Sciences | Iluvien | $250 | 2 payments
|
| Genentech | Lucentis | $102 | 1 payment
|
| Carl Zeiss Meditec | Opmi Lumera | $29 | 1 payment
|
| Novartis Pharmaceuticals | None | $26 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2022 | Their institution | $89,677 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2023 | Their institution | $83,229 |
| Genentech, Inc. · Flavoprotein Fluorescence Imaging in Patients With Diabetic Macular Edema. · 2022 | Their institution | $43,400 |
| Genentech, Inc. · Flavoprotein Fluorescence Imaging in Patients With Diabetic Macular Edema · 2025 | Their institution | $43,400 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2024 | Their institution | $40,493 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2025 | Their institution | $24,776 |
| Genentech, Inc. · A Phase 1 Sad MD in Diabetic Macular Edema · 2024 | Their institution | $21,700 |
| Genentech, Inc. · Lucentis · 2024 | Their institution | $21,700 |
| Apellis Pharmaceuticals, Inc. · Gale · 2021 | Their institution | $1,702 |
Professional record
- NPI
- 1073670477
- Licence
- CA C144368, NC 200000279California C144368: Current · expires 2028-03-31
- Group
- Stanford Health Care · County of Santa Clara
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1804 Embarcadero Rd, Suite 100, Palo Alto, CA, 94303
- NPI first listed
- 2007-01-03
- NPI last updated
- 2024-03-21
- NPI record certified
- 2024-03-21
This is when the NPI record was last certified, not a medical board exam.